IMA Group announced that its Pharmaceutical and MedTech divisions will present their capabilities as an all-in-one supplier specializing in the design and manufacture of innovative machines and ...

In commercial tablet or capsule operations, validation helps protect the site’s ability to produce, release, and supply product without repeated disruption. This article discusses validation as a ...

Discover a novel technology to standardize purification across a broad range of microbial proteins that accelerates and ...

Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a ...

In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...

Commercializing sustainability hinges on reframing it as risk mitigation and competitive advantage, supported by medium-to-long-term resilience planning and co-creation with suppliers rather than ...

Christy Owings, Thermo Fisher, discusses how customs delays and import complexity risk clinical trial supply chains in Latin America. Christy Owings, Vice President and General Manager of the Americas ...

Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...

Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...

The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...

Novartis's up-to-$3.2 billion licensing deal for Alteogen's ALT-B4 hyaluronidase enzyme is the fourth subcutaneous-conversion ...

Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...